Navigation Links
Keryx Biopharmaceuticals' KRX-0401 (Perifosine) Data Selected for Oral Presentation at the 50th Annual Meeting of the American Society of Hematology
Date:11/10/2008

cluding Pre-clinical Models)

Presentation Time: 5:30 PM - 7:30 PM

Location: Moscone Center, Hall A

Poster Board no.: I-115

MONDAY, DECEMBER 8th

Abstract 3691

TITLE: Phase I Results of Perifosine (KRX-0401) in Combination with

Lenalidomide and Dexamethasone in Patients with Relapsed or Refractory

Multiple Myeloma (MM)

Session Name: Myeloma - Therapy, excluding Transplantation Poster III

Presentation Time: 5:30 PM - 7:30 PM

Location: Moscone Center, Hall A

Poster Board no.: III-773

Pre-Clinical Poster Presentations:

MONDAY, DECEMBER 8th

Abstract 3663

TITLE: Combination of Nab-Rapamycin and Perifosine Induces Synergistic

Cytotoxicity and Antitumor Activity Via Autophagy and Apoptosis in

Multiple Myeloma (MM)

Session Name: Myeloma - Pathophysiology / Preclinical Studies excluding

Therapy Poster III

Presentation Time: 5:30 PM - 7:30 PM

Location: Moscone Center, Hall A

Poster Board no.: III-745

Abstract 1555

TITLE: Phenotypic and Functional Effects of Novel Akt Inhibitor

Perifosine on Immune System

Session Name: Lymphocytes and Lymphocyte Activation Poster I

Presentation Time: 5:30 PM - 7:30 PM

Location: Moscone Center, Hall A

Poster Board no.: I-660

Copies of the above referenced abstracts can be viewed online through the ASH website, http://www.hematology.org.

KRX-0401 (Perifosine) Mechanism of Action and Profile

KRX-0401 (Perifosine) is a novel, potentially first-in-class, oral anti-cancer agent that modulates Akt and a number of other key signal transduction pathways, including the JNK and MAPK pathways, all of which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. The effects of perifosine on Akt are of particular interest because of the importance of
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2008 Financial Results on Tuesday, November 11, at 8:30 A.M. EST
2. Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2008 Financial Results
3. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) to be Presented at the Upcoming American Society of Hematology Meeting in Atlanta, Georgia
4. Presentation Time Correction: Keryx Biopharmaceuticals Presents at 12:00pm, ET Tomorrow (Oct. 3) at William Blair & Company Small-Cap Growth Stock Conference
5. Morria Biopharmaceuticals Plc Announces Preliminary Results Regarding Inflammatory Markers From its Phase II Study in Allergic Rhinitis
6. XTL Biopharmaceuticals Announces Financial Results for the Year Ended December 31, 2007
7. Nabi Biopharmaceuticals Completes Sale of Nabi Biologics to Biotest AG
8. Nabi Biopharmaceuticals Announces Third Quarter 2007 Financial Results and Positive Vote from November 8, 2007 Special Stockholders Meeting
9. Early Results of Phase 2 Trial of Perifosine (KRX-0401) for the Treatment of Recurrent Malignant Gliomas Presented at the 12th Annual Scientific Meeting of Society for Neuro-Oncology
10. Lippincott Williams & Wilkins Selected as Publisher of the Journal of Neuroscience Nursing
11. Emdeon Selected by the Maryland Hospital Association to Power the Maryland Transaction Data Interchange
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... (PRWEB) July 22, 2014 As part ... School of Medicine at Mount Sinai have helped identify ... the risk of developing schizophrenia, in the largest genomic ... with 80,000 people. The findings, published online in Nature, ... schizophrenia, and could lead to new approaches to treating ...
(Date:7/22/2014)... Alan Mozes HealthDay Reporter ... used to treat moderate-to-severe allergic asthma appears to offer relief ... standard medications, new research suggests. The prescription drug -- ... U.S. Food and Drug Administration approval earlier this year for ... is taken at a high dose for a six-month period ...
(Date:7/22/2014)... team has identified protein "signatures" of genetic mutations ... cause of cancer deaths after lung cancer. , ... current issue of the journal Nature ... cancer, "will enable new advances" in diagnosing and ... a first-of-its-kind paper. I think it,s a very ...
(Date:7/22/2014)... 2014 The “Human Insulin Market ... Acting, Premixed), Modern Human Insulin (Rapid Acting, Long ... Novomix, Tresiba, Others) - Forecast to 2019” provides ... challenges, opportunities, current market trends, and strategies impacting ... estimates and forecasts of the revenue and share ...
(Date:7/22/2014)... (PRWEB) July 22, 2014 For more ... and cold storage consumers with dynamic, specialized ... and customer satisfaction. Offering 50-70% less energy requirements ... process. This process is completed through a non-chemical ... technologies also provide a 4.2 Micron droplet. The ...
Breaking Medicine News(10 mins):Health News:Mount Sinai Scientists and International Team Shed New Light on Schizophrenia in Largest Genomic Study Published to Date 2Health News:Mount Sinai Scientists and International Team Shed New Light on Schizophrenia in Largest Genomic Study Published to Date 3Health News:Mount Sinai Scientists and International Team Shed New Light on Schizophrenia in Largest Genomic Study Published to Date 4Health News:Asthma Drug May Help Those With Chronic Hives 2Health News:Asthma Drug May Help Those With Chronic Hives 3Health News:Vanderbilt discovery may advance colorectal cancer diagnosis and treatment 2Health News:Human Insulin Market Worth $42 Billion by 2019 - New Report by MarketsandMarkets 2Health News:Human Insulin Market Worth $42 Billion by 2019 - New Report by MarketsandMarkets 3Health News:Human Insulin Market Worth $42 Billion by 2019 - New Report by MarketsandMarkets 4Health News:Human Insulin Market Worth $42 Billion by 2019 - New Report by MarketsandMarkets 5Health News:Smart Fog Inc Announces Cold Storage Humidification Technology to be Exhibited at the 2014 Fresh Summit Convention & Expo 2Health News:Smart Fog Inc Announces Cold Storage Humidification Technology to be Exhibited at the 2014 Fresh Summit Convention & Expo 3
... pioneer and global market leader in acai, with certified ... nationwide from Whole Foods to Publix, Kroger and Safeway, ... false claims by acai scam campaigns and consumer watchdog ... locals for centuries, is a highly nutritious fruit scientifically ...
... in football as it hosts conference chaired by its medical director ... ... Gulf Breeze, FL (Vocus) March 27, 2009 -- The fourth annual ... Orthopaedics & Sports Medicine will attract top physicians, physical therapists ...
... Sky One,Medical, Inc. ("China Sky One Medical" or "the ... pharmaceutical company producing over-the-counter,drugs in the People,s Republic of ... call at 10:30 a.m. Eastern Daylight Time (EDT) on ... fiscal year 2008 financial,results. , ...
... concentrating in areas with high doctor/patient ratios, experts say ... and urban areas of the United States may soon ... for underserved and aging populations, a new study warns. ... areas with already established medical communities, a trend that ...
... School of Medicine have been named Early Career Scientists ... Iannis Aifantis, Ph.D. associate professor of pathology, co-director of ... Institute and Jeremy S. Dasen Ph.D., assistant professor of ... among 50 of the nation,s top scientists being honored ...
... passed today by the Democratically-controlled Michigan House of ... pockets of personal injury lawyers at the expense ... Commerce."By repealing Michigan,s lawsuit abuse protections, the supporters ... becomes a lawsuit magnet," said Wendy Block, Director ...
Cached Medicine News:Health News:Sambazon, World Leader in Acai, Stands up for the Amazonian Fruit's True Nutritional Properties 2Health News:Sambazon, World Leader in Acai, Stands up for the Amazonian Fruit's True Nutritional Properties 3Health News:Catastrophic Head and Neck Injuries Among Focus for NFL Team Physicians and Clinical Staff at Fourth Annual Injuries in Football Conference 2Health News:Catastrophic Head and Neck Injuries Among Focus for NFL Team Physicians and Clinical Staff at Fourth Annual Injuries in Football Conference 3Health News:China Sky One Medical, Inc. Announces Conference Call to Discuss Fourth and Fiscal Year 2008 Results 2Health News:Midwest and Northeast May Face Surgeon Shortage 2Health News:Two NYU Scientists Named Howard Hughes Medical Institute's early career scientists 2Health News:Two NYU Scientists Named Howard Hughes Medical Institute's early career scientists 3
(Date:7/21/2014)... , July 21, 2014 /PRNewswire-iReach/ -- Nitrosolution.com, a website ... , will celebrate its first anniversary in August. The ... designed to enhance the body,s ability to produce nitric ... is made up of a variety of phytonutrients and ... been found to increase nitric oxide production ...
(Date:7/21/2014)... YORK , July 21, 2014  EHE International, ... exams with a nationwide physician network, today announced that ... Las Vegas, NV has been named an ... the Las Vegas region now ... help proactively maintain their health. "EHE ...
(Date:7/21/2014)... ALBANY, New York , July 21, 2014 /PRNewswire/ ... market report published by Transparency Market Research "E-Clinical Solution ... and Forecast, 2014 - 2020," the global microfluidic device ... and is expected to grow at a CAGR of ... value of USD 6,515.3 million in 2020. ...
Breaking Medicine Technology:Up and Coming Nitric Oxide Supplements Company Nitrosolution.com Celebrates its One Year Anniversary 2EHE International Certifies Dignity Health Medical Group Nevada, LLC as Its Newest Partner 2E-Clinical Solution Software Market is expected to reach USD 6,515.3 million in 2020: Transparency Market Research 2E-Clinical Solution Software Market is expected to reach USD 6,515.3 million in 2020: Transparency Market Research 3E-Clinical Solution Software Market is expected to reach USD 6,515.3 million in 2020: Transparency Market Research 4E-Clinical Solution Software Market is expected to reach USD 6,515.3 million in 2020: Transparency Market Research 5
... Monogram,Biosciences, Inc. (Nasdaq: MGRM ) announced ... Pfizer Inc,s (NYSE: PFE ) phase III ... CCR5-tropic,HIV-1, increased efficacy was shown as a result ... of the enhanced version of Monogram,s Trofile(TM),Assay., ...
... Oct. 26 Paratek Pharmaceuticals, Inc. today,announced positive ... PTK,0796, a first-in-class aminomethylcycline (AMC). The Phase 2 ... (IV) forms of PTK 0796 to,Zyvox(R) in the ... infections (cSSSIs). Paratek,s trial met its primary safety ...
Cached Medicine Technology:Data Reported at ICAAC Indicates Selzentry(TM) Phase III Treatment-Naive Trial Shows Increased Efficacy When Used With Enhanced Trofile(TM) Assay 2Data Reported at ICAAC Indicates Selzentry(TM) Phase III Treatment-Naive Trial Shows Increased Efficacy When Used With Enhanced Trofile(TM) Assay 3Data Reported at ICAAC Indicates Selzentry(TM) Phase III Treatment-Naive Trial Shows Increased Efficacy When Used With Enhanced Trofile(TM) Assay 4Data Reported at ICAAC Indicates Selzentry(TM) Phase III Treatment-Naive Trial Shows Increased Efficacy When Used With Enhanced Trofile(TM) Assay 5Data Reported at ICAAC Indicates Selzentry(TM) Phase III Treatment-Naive Trial Shows Increased Efficacy When Used With Enhanced Trofile(TM) Assay 6Paratek Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy 2Paratek Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy 3Paratek Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy 4